Documente Academic
Documente Profesional
Documente Cultură
10-Feb-17
Top News
HEROMOTOCO concall highlights: Lupin concall update:
Good single digit growth for first half and better growth in R&D expenditure in 3QFY17 is 13% of sales.
second half in FY18. In last quarter company has acquired 21 generic brands from Japans
Overall recovery has been seen across the country but certain Shionogi.
parts of south and west regions are still taking time to recover Forex gain , lower cost & R&D exp. Help the company to improve
from demonetization issue. margins.
B32 Marriage season going ahead will trigger the pent up US revenue gained on account of new product launches in US.
demand. Customer consolidation and High single-digit Price erosion in US is
There could be some increase in RM cost due to rising ongoing.
commodity prices. 4 products are launched in US in Q3FY17.
Price hike taken in the range of Rs.500-1500 in January. This Management has guided that higher debt is on account of acquisition
hike covers some part of BS-IV compliance. and it will be re-paid in longer time frame.
Ad spend is 2.4 to 2.5% of sales. Management has maintained its capex guidance for FY17 is Rs. 1800-
Inventory level 6-7 weeks. 2000 Cr and Rs. 1500 Cr for FY18
Bank of India plans to raise about Rs 3,700 crore by the end of
LEAP program benefit till January is Rs.192 crore and
March 2017 . The bank plans to raise about Rs 1,000-1,500 crore by
management expects Rs.255 crore in FY17.
issuing Additional Tier-1 (AT-1) bonds and an equal amount by issuing
Capex guidance for FY17 is Rs.1200-1500 crore and Rs.1100 for
Tier-2 bonds
FY18.
Exports outlook does not look clear. (Major exports markets are Canada-based Brookfield Asset Management is likely to infuse around
Nigeria, Argentina and Mexico) Rs 1,000 crore inJaiprakash Power Ventures ( JPVL), people with direct
Company has started rolling out BS-IV compliance products knowledge of the development . JPVL has a debt of around Rs 12,000
crore on its books.
Tata Chemicals will invest Rs 595 crore to set up two facilities Aurobindo Pharma forayed into biosimilars with acquisition of four
in Andhra Pradesh and Gujarat to manufacture soluble dietary cell culture derived biosimilar products from Switzerland-based TL
fibres and silica. The Board of Directors approved an investment Biopharmaceutical AG. As part of the deal. TL will supply all the
in the nutritional solutions business of Rs 270 crore for setting developmental data for four molecules and Aurobindo will develop and
up of a state-of-the-art, biotechnology unit in Nellore district, market these products globally.
Andhra Pradesh for manufacturing of soluble dietary fibres with Sundaram-Clayton Ltd, the flagship company of USD 7 billion TVS
cutting-edge health benefits Group, has planned to invest Rs 750 crore as part of its plans to expand
its facilities in the domestic market besides setting up a greenfield unit
inthe United States.
TRADING IDEAS
Risk Disclosure & Disclaimer: This report/message is for the personal information of
the authorized recipient and does not construe to be any investment, legal or taxation
advice to you. Narnolia Securities Ltd. (Hereinafter referred as NSL) is not soliciting any
action based upon it. This report/message is not for public distribution and has been
furnished to you solely for your information and should not be reproduced or
redistributed to any other person in any from. The report/message is based upon publicly
available information, findings of our research wing East wind & information that we
consider reliable, but we do not represent that it is accurate or complete and we do not
provide any express or implied warranty of any kind, and also these are subject to change
without notice. The recipients of this report should rely on their own investigations,
should use their own judgment for taking any investment decisions keeping in mind that
past performance is not necessarily a guide to future performance & that the the value of
any investment or income are subject to market and other risks. Further it will be safe to
assume that NSL and /or its Group or associate Companies, their Directors, affiliates
and/or employees may have interests/ positions, financial or otherwise, individually or
otherwise in the recommended/mentioned securities/mutual funds/ model funds and
other investment products which may be added or disposed including & other mentioned
in this report/message.